UW Drug Interaction Database (DIDB)
The Drug Interaction Database (DIDB) part of UW Drug Interaction Solutions, was developed in the Department of Pharmaceutics, School of Pharmacy at the University of Washington and is designed to support research and regulatory scientists in their decision-making when evaluating PK-based drug interactions and drug safety.
The Drug Interaction Database displays highly detailed preclinical (in vitro, human) and clinical datasets with quantitative and qualitative information related to various intrinsic and extrinsic factors. These factors include interacting co-medications, excipients, food products, herbals, tobacco, organ impairment and genetics, that can affect drug exposure in humans.
The information is extracted from relevant publications and recent NDA/BLA reviews and common metrics (e.g., changes of drug exposure, oral clearance) for active compounds are used across all studies to allow metadata analysis of quantitative results.
The database is web-based and is updated daily by research scientists, experts in drug interactions, and members of the UW Drug Interaction Solutions team.
For more information: http://www.druginteractionsolutions.org
To get our latest news: Follow us on LinkedIn
Available Licenses
For Education/Government License/Not-for-Profit Organizations
When you are ready to license you can download below the applicable license agreement, fill out the license following the instructions on the first page, sign, and return it to UW CoMotion at license@uw.edu
For Pharmaceutical Company and Most Service Providers (such as preclinical and/or clinical CROs and R&D consulting firms)
When you are ready to license you can download below the applicable license agreement, fill out the license following the instructions on the first page, sign, and return it to UW CoMotion at license@uw.edu
For Specialty Service Providers (such as computer software companies developing tools for therapeutic development and providers of clinical decision support systems)
To license this product please contact UW CoMotion at license@uw.edu
-
swap_vertical_circlelibrary_booksReferences (6)
- McFeely SJ, Ritchie TK, Ragueneau-Majlessi I (2020 Jan), Variability in In VitroOATP1B1/1B3 Inhibition Data: Impact of Incubation Conditions on Variability and Subsequent Drug Interaction Predictions, Clin Transl Sci., 13(1), 47-52
- Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I (2018 Jun), Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016, Drug Metab Dispos, 46(6), 835-845
- Yu J, Zhou Z, Tay-Sontheimer J, Levy RH, Ragueneau-Majlessi I (2017 Sep), Intestinal Drug Interactions Mediated by OATPs: A Systematic Review of Preclinical and Clinical Findings, J Pharm Sci, 106(9), 2312-2325
- Hachad H, Overby CL, Argon S, Yeung CK, Ragueneau-Majlessi I, Levy RH (2011 Jul), e-PKGene: a knowledge-based research tool for analysing the impact of genetics on drug exposure, Hum Genomics, 5(5), 506-15
- Hachad H, Ragueneau-Majlessi I, Levy RH (2010 Oct), A useful tool for drug interaction evaluation: the University of Washington Metabolism and Transport Drug Interaction Database, Hum Genomics, 5(1), 61-72
- Levy RH, Hachad H, Yao C, Ragueneau-Majlessi I (2003 Oct), Relationship between extent of inhibition and inhibitor dose: literature evaluation based on the metabolism and transport drug interaction database, Curr Drug Metab, 4(5), 371-80
-
swap_vertical_circlecloud_downloadSupporting documents (2)Additional files may be available once you've completed the transaction for this product. If you've already done so, please log into your account and visit My account / Downloads section to view them.